Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal polysaccharide diphtheria conjugate vaccine
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W-135. The vaccine contains purified capsular polysaccharides from these four serogroups of *Neisseria meningitidis* that are covalently linked (conjugated) to a carrier protein—diphtheria toxoid. This conjugation enhances the immune response by promoting T-cell dependent immunity and immunological memory. The primary indication is the prevention of invasive meningococcal disease in individuals at increased risk or as part of routine immunization schedules for children and adolescents. It does not protect against group B *Neisseria meningitidis*[1][4][6][8].
- Brand names
- MenactraMenveo
- Other names
- Meningococcal vaccine diphtheria conjugateMeningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Meningococcal polysaccharide diphtheria conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal polysaccharide diphtheria conjugate vaccine.